Skip to content

Application of Shalmali Gel on face with oral intake of Khadiratriphaladi Kwatha Ghana capsule in management of Acne vulgaris

Efficacy of Khadiratriphaladi Kwatha Ghana (capsule) and Shalmali gel in the management of Yuvanpidika (Acne vulgaris) in Adolescents -A Randomized Placebo Controlled Clinical Trial - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065630
Enrollment
62
Registered
2024-04-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

None listed

Sponsors

All India Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adolescents aged between 10-16 years of either gender having classical features of Yuvanpidika. 2.Adolescent has an Investigator’s Global Assessment (IGA) score of 2-3 [0 (clear) to 4 (severe) scale]. (Mild to moderate cases of facial Acne vulgaris) 3.Adolescents/ Parents willing to give written informed assent/ consent. 4.Adolescents and parent/guardian (if applicable) are willing to comply with study instructions and return to the OPD for required visits.

Exclusion criteria

Exclusion criteria: 1.Adolescents having any other skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical or systemic therapy. 2.Adolescents having nodulocystic acne. 3.Adolescents having any systemic diseases and auto immune disorder. 4.Adolescents currently enrolled in an investigational drug or device study. 5.Adolescents who have received an investigational drug or has been treated with an investigational device within 30 days prior to the initiation of treatment (Baseline). 6.Adolescents having known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles 7.Adolescents and parent/guardian (if applicable) are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function. 8.Adolescent has used any of the following topical anti-acne preparations or procedures on the face: a.Topical anti-acne treatments including, but not limited to, over-the-counter (OTC) acne cleansers or treatments, benzoyl peroxide, antibiotics, azelaic acid, sulfa based products, corticosteroids and salicylic acid within two (2) weeks of the initiation of treatment. b.Retinoids, including tazarotene, adapalene, tretinoin, within four (4) weeks of the initiation of treatment. c.Light treatments, microdermabrasion, or chemical peels within eight (8) weeks of the initiation of treatment. 9.Adolescent has used the following systemic anti-acne medications: a.Corticosteroids (including intramuscular and intralesional injections) within four (4) weeks of the initiation of treatment. Inhaled, intranasal or ocular corticosteroids are allowed if use is stable (stable use is defined as dose and frequency unchanged for at least four (4) weeks prior to the initiation of treatment). b.Antibiotics within four (4) weeks of the initiation of treatment with the exception of five (5) days or less of antibiotic therapy during this period, BUT with no antibiotics use permitted within one (1) week prior to the initiation of treatment. c.Spironolactone within eight (8) weeks of the initiation of treatment with the exception of five (5) days or less of spironolactone therapy during this period, BUT with no spironolactone use permitted within one (1) week prior to the initiation of treatment. d.Retinoid therapy within six (6) months of the initiation of treatment e.Other systemic therapy which may materially affect the subject’s acne in the opinion of the investigator.

Design outcomes

Primary

MeasureTime frame
Reduction in the IGA scoreTimepoint: 4 weeks, 8 weeks,12 weeks

Secondary

MeasureTime frame
1.Reduction in clinical features of Yuvanpidika as per classical texts of Ayurveda. 2.Improvement in CDLQI 3.Reduction in Lesion counts as evidenced by photographs.Timepoint: 4 weeks, 8 weeks,12 weeks

Countries

India

Contacts

Public ContactDr Diksha Nighah

All India Institute of Ayurveda

ayuarun@gmail.com8506821947

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026